Cellectar Biosciences (CLRB) EBT (2010 - 2026)
Cellectar Biosciences (CLRB) posted EBT of -$5.8 million for Q4 2025, down 16.76% sequentially from -$5.0 million in Q3 2025, and up 95.14% YoY from -$3.0 million in Q4 2024.
Cellectar Biosciences (CLRB) EBT (2010 - 2026) Analysis & Trends
Cellectar Biosciences has reported EBT for 16 years, with the latest figure at -$5.8 million in Q4 2025.
- Quarterly EBT rose 95.14% year-over-year to -$5.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$24.0 million (up 85.12% YoY) and the FY2025 annual result came in at -$21.8 million, up 51.05% from the prior year.
- EBT slipped to -$5.8 million in Q4 2025 per CLRB's latest filing, from -$5.0 million in the prior quarter.
- Over five years, EBT peaked at -$5.0 million in Q3 2025 and troughed at -$120.2 million in Q4 2024.
- A 5-year average of -$17.7 million and a median of -$7.7 million in 2022 frame the typical range for EBT.
- The sharpest annual moves came in 2022 and 2025: EBT tumbled 1205.38% in 2022, then surged 95.14% in 2025.
- Over 5 years, EBT stood at -$6.2 million in 2021, then sank by 1205.38% to -$80.3 million in 2022, then soared by 82.29% to -$14.2 million in 2023, then slumped by 744.87% to -$120.2 million in 2024, then soared by 95.14% to -$5.8 million in 2025.
- According to Business Quant data, EBT over the past three periods registered -$5.8 million, -$5.0 million, and -$6.6 million for Q4 2025, Q3 2025, and Q2 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 1.39 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 1.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 541.00 Mn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | -767.00 Mn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 312.46 Mn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 177.81 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | -11.37 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 81.49 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | -264.70 Mn |
| 10 | Cellectar Biosciences | 6.63 Mn | 6.63 Mn | - | -7.06 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -9.34 Mn |
| Dec 31, 2025 | -5.85 Mn |
| Sep 30, 2025 | -5.01 Mn |
| Jun 30, 2025 | -6.62 Mn |
| Mar 31, 2025 | -6.56 Mn |
| Dec 31, 2024 | -120.23 Mn |
| Sep 30, 2024 | -14.02 Mn |
| Jun 30, 2024 | -14.43 Mn |
| Mar 31, 2024 | -12.77 Mn |
| Dec 31, 2023 | -14.23 Mn |
| Sep 30, 2023 | -9.67 Mn |
| Jun 30, 2023 | -8.57 Mn |
| Mar 31, 2023 | -8.85 Mn |
| Dec 31, 2022 | -80.35 Mn |
| Sep 30, 2022 | -8.03 Mn |
| Jun 30, 2022 | -7.44 Mn |
| Mar 31, 2022 | -6.14 Mn |
| Dec 31, 2021 | -6.15 Mn |
| Sep 30, 2021 | -6.19 Mn |
| Jun 30, 2021 | -6.44 Mn |